INMB — Inmune Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $178.36m
- $157.43m
- $0.01m
Annual cashflow statement for Inmune Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -12.1 | -30.3 | -27.3 | -30 | -42.1 |
| Non-Cash Items | 3.11 | 4.92 | 7.48 | 7.59 | 7.68 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.044 | -3.09 | -2.86 | 10.4 | 1.04 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -8.94 | -28.5 | -22.7 | -12 | -33.4 |
| Capital Expenditures | — | -15 | 0 | — | — |
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | — | -15 | 0 | — | — |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 23.9 | 96.4 | 0.729 | -4.22 | 18.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 15 | 52.8 | -22.7 | -16.3 | -14.9 |